title: Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor.
abstract: We describe the use of abciximab to prevent rethrombosis of the basilar artery after transluminal angioplasty. A 60-year-old patient with vertebral basilar insufficiency and acute occlusion of the basilar artery underwent revascularization with urokinase and angioplasty. Despite the repeated use of urokinase and angioplasty under anticoagulation with heparin, the basilar artery immediately rethrombosed. In a final attempt to prevent rethrombosis, abciximab was administered before the final angioplasty, resulting in a widely patent basilar artery and no rethrombosis.
authors.affiliation: Department of Neuroradiology, Cleveland Clinic Foundation, Ohio 44195, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Wallace
authors.forename: A J
authors.initials: AJ
authors.lastname: Furlan
authors.forename: D J
authors.initials: DJ
authors.lastname: Moliterno
authors.forename: G H
authors.initials: GH
authors.lastname: Stevens
authors.forename: T J
authors.initials: TJ
authors.lastname: Masaryk
authors.forename: J
authors.initials: J
authors.lastname: Perl
mesh_terms: D000077284:Abciximab; D000800:Angioplasty, Balloon; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001488:Basilar Artery / Q000000981:diagnostic imaging; D002533:Cerebral Angiography; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D002542:Intracranial Embolism and Thrombosis / Q000097:blood / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000502:physiology; D012008:Recurrence; D019233:Retreatment; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D006495:Heparin, Low-Molecular-Weight; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator; D000077284:Abciximab